Immutep Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025
A Proffered Paper oral presentation will detail results from EFTISARC-NEO, a Phase II investigator-initiated trial in resectable soft tissue sarcoma, and data from the INSIGHT-003 Phase I investigator-initiated trial in first-line non-small cell lung cancer (1L NSCLC) has been accepted for poster presentation. Additionally, an abstract on the Company's pivotal TACTI-004 Phase III in 1L NSCLC has been accepted for a Trials in Progress ePoster. Details of the presentations are as follows:
Title:
EFTISARC-NEO: A phase II study of neoadjuvant eftilagimod alpha, pembrolizumab and radiotherapy in patients with resectable soft tissue sarcoma
Presenter:
Katarzyna Kozak, M.D., Ph.D., Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
Session Category:
Proffered Paper
Session Title:
Sarcoma
Presentation #:
2686O
Date and Time:
Sunday, 19 October 2025 at 16:30 – 18:00 PM CET
Title:
Eftilagimod alpha (soluble LAG-3 protein) combined with 1st line chemo-immunotherapy in metastatic non-squamous non-small cell lung cancer (NSCLC) –Updates from INSIGHT-003 (IKF614)
Presenter:
Dr. med. Akin Atmaca, Department of Hematology and Oncology, Krankenhaus Nordwest, UCT-University Cancer Center, Frankfurt, Germany
Session Category:
Poster
Session Title:
NSCLC, metastatic
Presentation #:
1857P
Date and Time:
Saturday, 18 October 2025 at 12:00 – 12:45 PM CET
Title:
TACTI-004, a double-blinded, randomised phase 3 trial of eftilagimod alfa plus pembrolizumab (P) + chemotherapy (C) vs placebo + P + C in 1st line advanced/metastatic NSCLC
Presenter:
Prof. Dr. med. Hans-Georg Kopp, Robert Bosch Hospital, Stuttgart, Germany
Session Category:
ePoster
Session Title:
NSCLC, metastatic
Presentation #:
2086eTiP
Proffered Papers at ESMO are oral presentations of original data of superior quality, followed by expert discussion and perspectives.
Abstracts will be made available on the ESMO website on 13 October 2025 at 00.05 CET. The posters will be available on the Posters & Publications section of Immutep's website after their presentations.
About ImmutepImmutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3's ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.
Australian Investors/Media:Eleanor Pearson, Sodali & Co.+61 2 9066 4071; eleanor.pearson@sodali.com
U.S. Media:Chris Basta, VP, Investor Relations and Corporate Communications+1 (631) 318 4000; chris.basta@immutep.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Measuring for success: innovation comes to ore screening
The mining industry is facing up to a new reality that has, for some time, been taking root: ore grades are declining, deposit complexity is increasing and becoming less economic, while competition for mineral resources such as water and energy is becoming tougher. 'How do we approach these challenges in a technological sense, is what many of us are asking,' says David Miljak, research programme director for sensing and sorting, mineral resources at the Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australia's preeminent national science agency. For the energy-intensive ore screening and sorting part of the mining process, Miljak and his team, along with other start-ups and academics, are looking to provide the answer to this question. Rocks are usually sorted particle by particle using methods like X-ray transmission (XRT). However, there is significant scope for improving this process with advanced technologies that offer more informed and faster analysis and, ultimately, better data capture, according to experts like Miljak. He and his team are advancing radio frequency, X-ray and nuclear sensing instrumentation for high-throughput conveyor belt systems used early in the mining process that can 'interrogate' the rocks. 'What we want to know is how much copper, for example, is in the rocks; if we know that accurately and fast enough, we can divert them for processing and reject the rocks that are low in copper and aren't economic to mine,' he explains. 'This can have enormous benefits in uplifting the ore grade, the economics and the sustainability of the operation.' In this way, low-grade rocks do not need to be crushed, meaning the overall process requires less energy and water usage. It also minimises the material entering tailings dams. Ore screening technology Miljak, who has almost 30 years' experience in radio frequency-based technology, was involved in developing, over 15 years, magnetic resonance technology (MRT) that was commercialised through NextOre, a company spun out of CSIRO in 2017. In March, NextOre announced its first solution for analysing ore transported by underground copper trucks, an adaptation of its conveyor belt application. MRT is a form of radio frequency spectroscopy that can be used to count the atoms of a target metal in a sample. It works by subjecting ore to pulses of radio waves set to the signature frequency of the target mineral. The resonating ore produces a radio field burst, known as a 'spin echo', which is quantitatively measured by the sensor. The data generated by the MRT analyser is presented as real-time weight measurements of the target metal which, combined with weightometer readings, provides real-time grade as weight per cent of the material. The technology can do this for 50 tonnes (t) of material in under a minute, according to NextOre, providing mining operations with real-time data that informs ore routing decisions. It has been demonstrated at several operations including First Quantum Minerals' Kansanshi mine in Zambia, Lundin's Candelaria mine in Chile and Capstone's Cozamin mine in Mexico, with a trial at Cozamin reporting a 7.5% increase in copper production without additional mining. This technology is related to magnetic resonance imaging machines used in medicine, but must be adapted to mining conditions that are harsh and dusty. 'These technologies have been around for decades, but what we are trying to do is tweak the physics to make it work in minerals, which is actually a huge undertaking; you have got to re reinvent how you transmit the radio waves onto the targets," says Miljak. Hyperspectral sensing technology Another spin-out innovating in this space is Hypermine, born from VTT, a Finland-based European research organisation. Its technology combines laser illumination, hyperspectral sensing and proprietary machine-learning algorithms, to sort the valuable minerals at the earliest stage of the mining process. The company, which in June announced a successful closure of its seed funding round, claims the technology helps cut energy use by 10% and can reduce ore flotation acids and water usage by 15%. It does this by making stockpiling decisions 100-times more accurate, says CTO Mikhail Mekhrengin. He adds that the company is already detecting alumina contamination in its iron mines and sulphate contamination in copper mines, with four systems implemented in customer operations in Brazil, Chile and South Africa. 'Hypermine enables actionable data for each shovel or truck load, as well as the potential of a 3–10% higher mining profitability due to fewer valuable materials being lost into waste, less gangue in the process and more consistent feed to processing plants,' Mekhrengin says. Similarly, Germany-based Steinert is providing sensor-based sorting technology to uncover ore's composition in real time, adopted by Terra Goyana bauxite mining operation in Brazil. Successful trials at the site showed the technology could remove contaminants at an improved rate. Multiple complementary solutions These solutions can work in tandem with to X-ray technology, experts say. The difference, Mekhrengin explains, is that X-ray fluorescence (XRF) is based on elemental analysis to provide ore-grade information, whereas laser spectroscopy or hyperspectral sensing are optical technologies that provides molecular content of the material, including mineral content and concentrations, lithologies, rock type and chemistry. 'Why is mineralogy/rock type important? Because metals are never presented in a pure form in nature. They are enclosed in minerals. It is hard to impossible to translate elemental information to mineralogical data. In the perfect case, you need both,' he says, adding: 'On top of XRF, mineralogy is crucial to understanding how to process the mined material.' A spokesperson for NextOre adds that XRT is applied only in rock-by-rock, or 'particle' sorting applications, is cost intensive and can become very complex and expensive for higher throughput applications greater than 200 tonnes per hour (tph). 'Conversely, magnetic resonance is particularly well suited for bulk applications, extending currently to 6,500tph and almost certain to go higher.' Improving processing plants In addition to sorting, CSIRO and Miljak are applying similar techniques to measure what is in flotation plants during the extraction process. Technology that can quantify the mineral phases changing in real time could help operators address or mitigate 'upsets' in the mineral processing that spoil the entire operation, says Miljak. It could lead to mitigating actions such as changing the feedstock to blend out the bad mineral actor. 'It could be a certain mineral that makes the recovery process go off; it is a disruption. We can pick these up very quickly with the technology we have – this is a unique capability we have developed in the last 5–10 years,' he says. "If operators are not privy to these big deviations, recoveries can drop, so stopping them earlier could lead to higher yields. Over a long period, increasing recovery by even a few per cent for a big mine can potentially provide thousands of tonnes of more products – a fortune depending on what commodity is being mined.' CSIRO is working with some companies to pilot its "robust bits of technology" but is also looking for additional mining partners. Innovations in screening Further down the sorting and crushing process, Weir recently launched the ETX250, which it says is the largest double deck banana screen in the world for separating big and small rocks. The company says the screen, which is run by only two exciters, could reduce energy consumption by 40%, further supporting miners sustainability targets and reducing rising energy costs. 'Having only two exciters [rather than three] reduces the amount of inventory the customer has to keep, as well as maintenance, while giving better fine screening efficiency because we can run the exciter at a higher speed,' explains Corné Kleyn, global product manager at The Weir Group. The company recently sold 12 to a high profile mining operation in Pakistan. Incorporating AI into minerals screening and sorting The next step for data-driven technologies is coupling them with AI and machine learning (ML). While this is not Miljak and his team's focus, he says there are "big overlays". 'There is a beautiful train of data here that can be paired with AI ML, neural nets, and so on, that can be used to improve process based on historical data and to predict problems,' he explains. 'I think part of our problem is people aren't used to having mineral phase data in real time. So, it would be a new research endeavour to try and make the best of the data flows to improve it even further.' Nicolaas Steenkamp, an independent consultant who is a geologist by training, says AI could be valuable for improving these processes. 'Today, X-ray transmission technologies used in the mining industry do thousands of millions of calculations for each individual grain and that data is just discarded, it doesn't feed into production, but this could be processed in the cloud to give a much better insight into production,' he says. 'That can inform your processing plant in terms of the type of material it can expect to come through, enabling them to regulate the agents they will need to add to a specific processing cycle.' However, this is mostly "blue sky or proof of concept" technology right now, he adds. Vision for the future Steenkamp says the key driver for adopting these technologies is ultimately processing less ore, so a project is using less water, power and leaching agents to get a higher grade, while reducing the tailings. Wheaton Precious Metals president and CEO Randy Smallwood, a proponent of innovation in the mining industry, agrees these are important drivers for technology adoption. The company's Future of Mining Challenge awarded ReThink Milling $1m (C$1.37m) for its innovative milling technologies, which are estimated to reduce the energy use in comminution by more than half. However, as Steenkamp notes, for the bigger players, investing in cutting-edge technology is not a high priority as most are still operating at margins that mean they don't need to invest in high-cost equipment. For the small and medium operators, the cost often precludes them from adopting it. Although some industries, such as the diamond sector, are more used to using different types of technology and will therefore likely have more confidence to adopt, he adds. 'At the end of the day, you have got to have someone that is willing to be a participant and then be willing to share that data into the market, which can then convince your larger players to start adopting it,' he says. Miljak acknowledges there is general "inertia" within the industry when it comes to piloting and adopting new technologies but says there are "some really good innovation teams and individuals that are really trying to make a difference in the industry". 'My view is it will be an important lever for the future, if we can get a whole raft of technologies and innovators into this mining space to transform mining into manufacturing-type process, where real-time data can keep people safe and productivity high. That is the longer-term vision of CSIRO,' he concludes. "Measuring for success: innovation comes to ore screening" was originally created and published by Mining Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Brachytherapy Devices Market is Growing at CAGR of 6.7% During 2025 -2031 to Reach US$534.20 Million
NEW YORK, Aug 4, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the Brachytherapy Devices Market is witnessing significant growth due to the rising incidence of cancer worldwide and technological advancements in brachytherapy devices. The Brachytherapy Devices Market value is expected to reach US$534.20 million by 2031 from US$343.57 million in 2024; the market is anticipated to register a CAGR of 6.7% during 2025–2031. The market growth is attributed to the rising incidence of cancer worldwide, the aging population, and the technological advancements in brachytherapy devices. The Brachytherapy Devices Market analysis focuses on advancements such as MRI-compatible applicators and real-time imaging integration that play a vital role in the market growth. The report runs an in-depth analysis of market trends, key players, and future opportunities. Check valuable insights in the Brachytherapy Devices Market report. You can easily get a sample PDF of the report - Overview of Brachytherapy Devices Market Report Findings Rising Incidence of Cancer Worldwide:As per the GLOBOCAN 2020 report, more than 28.4 million new cancer cases are expected to be reported by 2040. An aging population, lack of physical activity, exposure to pollutants in the environment, and alterations in diet lead to increased rates of an internal radiation treatment, is ideal for the treatment of prostate, cervical, breast, and skin cancers. It allows for the radiation to be targeted directly to the tumor and avoid the surrounding healthy tissues, with reduced side effects and improved recovery times. Thus, brachytherapy is becoming increasingly popular among oncologists and cancer remains among the major causes of mortality globally, demand for effective, low-invasive, and affordable treatment procedures is rising. Brachytherapy is meeting this demand, particularly in facilities where it might not be possible to access highly advanced external radiation facilities. Thus, the increasing burden of cancers worldwide propels the market growth. Technological Advancements in Brachytherapy Devices:Advances in the area are improving the accuracy, safety, and effectiveness of treatments, making brachytherapy a progressively appealing choice for cancer technological advancements include the creation of high-dose rate (HDR) and low-dose rate (LDR) machines, which provide more accurate radiation delivery. HDR machines provide for administering higher doses of radiation in shorter times, making treatment faster and more convenient for patients. MRI-compatible applicators and integration of sophisticated imaging are providing better tumor localization and online monitoring of treatment. These advances allow clinicians to target tumors effectively with less exposure to healthy tissues in the proximity. The robot-assisted platforms provide higher accuracy and precision, particularly in challenging anatomical areas. In addition, miniaturization and mobility of brachytherapy equipment are facilitating treatments, especially in developing advances in technology are making brachytherapy more effective and safer but and increasing its uses in treating a broader spectrum of cancers. Consequently, the greater uptake of these machines is contributing to their adoption and setting the limits of cancer treatment even higher. Geographical Insights: In 2024, North America led the market with a substantial revenue share, followed by Europe and Asia Pacific. Asia Pacific is expected to register the highest CAGR during the forecast period. Stay Updated on Brachytherapy Devices Market Trends: Brachytherapy Devices Market Segmentation Based on product, the Brachytherapy Devices Market is segmented into seeds, brachytherapy afterloaders and applicators, and electronic brachytherapy. The brachytherapy afterloaders segment held the largest market share in 2024. In terms of type, the Brachytherapy Devices Market is categorized into high-dose rate brachytherapy implant and low-dose rate brachytherapy implant. The low-dose rate brachytherapy implant segment dominated the market in 2024. By application, the Brachytherapy Devices Market is segmented into breast cancer, cervical cancer, prostate cancer, lung cancer, and others. The prostate cancer segment dominated the market in 2024. Per end user, the Brachytherapy Devices Market is divided into hospitals and specialty clinics, ambulatory surgical centers, and others. The hospitals and specialty clinics segment dominated the market in 2024. The Brachytherapy Devices Market is segmented into five major regions: North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. Competitive Strategy and Development Key players: Elekta, Varian Medical Systems, Inc., BEBIG Medical, Theragenics Corporation, IsoAid, Siemens Healthineers AG, BXTA, BD, and Eckert and Ziegler are among the major companies operating in the Brachytherapy Devices Market. Trending topics: Advancements in Imaging Technologies, Government Initiatives and Cancer Treatment Programs, Technological Advancements in Brachytherapy Devices, Integration of Artificial Intelligence (AI) and Robotics in brachytherapy, etc. Headlines on Brachytherapy Devices Market Artemis Hospital Announces the Launch of Brachytherapy Services, Expanding Advanced Cancer Care Papua New Guinea Resumes Radiotherapy, Starts Brachytherapy Services with IAEA Support BEBIG Medical Launches SagiNova Brachytherapy System at Father Muller Hospital as a Part of New Healthcare Wing Medanta Patents MAOLO Brachytherapy Device For Advanced Cervical Cancer Treatment Elekta Expands Brachytherapy Portfolio With Acquisition of iCad Inc.'s Xoft Business CivaTech Oncology Receives FDA Approval for CivaSheet Brachytherapy Device Get Premium Copy of Brachytherapy Devices Market Size and Growth Report by 2031 at: Conclusion The growth of the Brachytherapy Devices Market is fueled by the increasing prevalence of cancer, advances in technology, and soaring demand for minimally invasive treatment options. The high-dose rate (HDR) systems, MRI-compatible applicators, and robotic-assisted devices are increasing the accuracy of treatment and speeding up patient recovery. Further, there is a growing demand for affordable and patient-centric therapies, particularly in areas that have poor access to conventional cancer therapy. With increasing uses in prostate, breast, and cervical cancers, the demand for brachytherapy is surging, with better results and accessibility in cancer therapy. The report from The Insight Partners provides several stakeholders—including manufacturers of seeds, brachytherapy afterloaders and applicators, and electronic brachytherapy devices—with valuable insights to navigate this evolving market landscape and unlock new opportunities. Trending Related Reports: Brachytherapy After Loaders Market Strategies, Top Players, Growth Opportunities, Analysis and Forecast by 2031 Cancer Therapy Market Scope, Share, and Size by 2031 Pancreatic Cancer Therapy Market SWOT Analysis by 2031 Lung Cancer Therapy Market Research Report by 2030 Cancer Biopsies Market Trends, Share, and Growth – 2031 Cervical Cancer Diagnostics and Therapeutics Market Size 2031 Kidney Cancer Therapeutics And Diagnostics Market Size 2031 Cancer Biopsies Market Trends, Share, and Growth - 2031 Thyroid Cancer Diagnostics Market Growth and Share by 2031 About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact Us:If you have any queries about this report or if you would like further information, please get in touch with us:Contact Person: Ankit MathurE-mail: +1-646-491-9876 Logo: View original content: SOURCE The Insight Partners Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Medscape
2 hours ago
- Medscape
Misinterpreting Words and Gestures in Medicine
This transcript has been edited for clarity. Hello. I'm David Kerr, professor of cancer medicine at University of Oxford. Today I'd like to talk about words and gestures, and how we can communicate unconsciously with patients in ways where we can end up being misunderstood. In the clinic on Friday, one of our patients, somebody we looked after for quite a long time, had evidence of oligometastatic recurrent colorectal cancer. By that, I mean the tumor had come back in three small spots within the peritoneal cavity. She's had multiple chemotherapies and we've done hepatic resections. We looked after her for 4.5 years with her metastatic disease and she's remained remarkably well, fully fit and active, and has been taking care of her young family and so on. What we thought that we would do for her treatment would be to offer, with my specialist colleagues in Oxford, stereotactic body radiation therapy (SBRT). This is very highly focused radiotherapy — spot welding, if you like — that can be delivered, with fantastic accuracy, safely to small areas of disease. We had arranged for her to see one of my senior colleagues in Oxford. The way that our NHS communicates with our patients is: A letter goes out saying, 'You have an appointment to see Professor Kerr and Dr Muirhead,' a fantastic radiotherapy colleague. Of course, our literate, clever patient looked up who Dr Muirhead was, and she saw the word "palliative" splashed across all the work that Rebecca does. Immediately, because that word was used, she assumed that she'd come to the end of the road, that there was nothing effective that we could offer for her treatment. Quite the opposite was the case, but the use of the word "palliative," to her mind, meant palliative care, end of care, and imminent death. For those of us who were somehow forced to do Latin to get into medical school, it comes from palliare, the Latin word for "to cloak" or "to hide." This was a word that was just utterly, completely misinterpreted, and the 2 weeks between receiving a letter and meeting me in a clinic had been the worst 2 weeks of the patient's life over the past 4.5 years. You can imagine the tears of joy when we explained exactly what it was we were going to do. It reminded me of another time, when I was a very young doctor in Glasgow, a senior registrar in my mid-twenties. I had looked after a young woman about the same age as me with metastatic ovarian cancer, along with my boss, Stan Kaye, another fantastic oncologist. We looked after her well and continually, but the disease caught up with her eventually. We were very active at that stage, one of the first centers in Europe to be involved in phase 1 trials with the National Cancer Institute. I wanted to explain that we could offer her a position in one of the phase 1 trials that we were doing, but of course, as a prelude to that, I had to explain that we had no more conventional treatment to offer. I come from the west of Scotland. We're not a very naturally tactile group of male human beings, but I leaned over, held her hand, and explained the situation, thinking really nothing of that small gesture. Later in her illness, as she did inch closer to death, we continued to look after her and to palliate — that word again. She said that the single scariest thing that she remembers of all the journey that we'd been over for all those years was when I held her hand, because she thought it must be very, very bad indeed for that young doctor to reach out, to hold her hand, and just to be gentle and kind. Words and gestures need to be chosen carefully. But, clearly unconsciously, whether aware of it or not, we're sending subliminal messages out to our patients. We may not be able to control them, but it's interesting how patients can interpret and misinterpret what we see and sometimes do. I'd be really interested in your own experiences, if you've come across anything even remotely similar. As always, thanks for listening. For the time being, Medscapers, ahoy. Thank you.
